NEW YORK, December 21, 2016 /PRNewswire/ --
On Tuesday, US markets saw broad based gains with all nine sectors finishing the trading session in green. The NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 also ended yesterday's session in positive territories. Building on the bullish momentum, Stock-callers.com reviews the following Biotech stocks: Inovio Pharmaceuticals Inc. (NASDAQ: INO), 22nd Century Group Inc. (NYSE MKT: XXII), Omeros Corporation (NASDAQ: OMER), and Cerulean Pharma Inc. (NASDAQ: CERU). Download the free research reports on these stocks today: http://stock-callers.com/registration
Plymouth Meeting, Pennsylvania headquartered Inovio Pharmaceuticals Inc.'s stock finished Tuesday's session 0.29% lower at $6.93 with a total volume of 986,180 shares traded. Inovio Pharma's shares have advanced 0.58% in the past one year. The Company's shares are trading below its 50-day and 200-day moving averages by 6.70% and 22.18%, respectively. Shares of Inovio Pharma, which develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases, have a Relative Strength Index (RSI) of 39.32. See our free and comprehensive research report on INO at: http://stock-callers.com/registration/?symbol=INO
On Tuesday, shares in Clarence, New York headquartered 22nd Century Group Inc. ended the session 4.57% higher at $1.03 with a total volume of 2.77 million shares traded. The stock is trading 5.45% above its 200-day moving average. Moreover, shares of the Company, which provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding, have an RSI of 49.14. XXII free research report PDF is just a click away at: http://stock-callers.com/registration/?symbol=XXII
On Tuesday, shares in Seattle, Washington-based Omeros Corp. recorded a trading volume of 279,500 shares. The stock ended the day 0.28% higher at $10.85. The Company is trading above its 50-day moving average by 6.16%. Furthermore, shares of Omeros, which discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system, have an RSI of 50.26. Sign up for your complimentary report on OMER at: http://stock-callers.com/registration/?symbol=OMER
Waltham, Massachusetts-based Cerulean Pharma Inc.'s stock declined 2.95%, to close the day at $0.76. The stock recorded a trading volume of 149,374 shares. Cerulean Pharma's shares have advanced 1.43% in the last one month. Shares of the Company, which develops nanotechnology-based therapeutics in the areas of oncology and other diseases in the US, are trading 2.23% and 59.46% below its 50-day and 200-day moving averages, respectively. Additionally, the stock has an RSI of 46.54. Register for free on Stock-Callers.com and download the latest research report on CERU at: http://stock-callers.com/registration/?symbol=CERU
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA